A 104 Week, Randomized, Double Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy.

A 104 Week, Randomized, Double Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy.